| Chen, Ling |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
| Completed | 3 | 226 | Europe, Canada, US, RoW | Bentracimab (PB2452) Infusion | SFJ Pharmaceuticals, Inc. | Hemorrhage, Urgent Surgery, Invasive Procedure | 09/24 | 09/24 | | |
NCT05420324: A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma |
|
|
| Completed | 2 | 20 | RoW | YH003, Pembrolizumab, albumin paclitaxel | Eucure (Beijing) Biopharma Co., Ltd | Mucosal Melanoma | 03/24 | 03/24 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
NCT05868083: The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma |
|
|
| Recruiting | 1 | 16 | RoW | SNC-109 CAR-T Cells | Shanghai Simnova Biotechnology Co.,Ltd., Chinese PLA General Hospital | Recurrent Glioblastoma Multiforme | 05/24 | 08/24 | | |
| Recruiting | N/A | 80 | US | Dexcom G6, Dexcom G6 blinded sensor | University of California, Davis, DexCom, Inc. | Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes | 03/25 | 12/25 | | |
| Dong, Yugang |
NCT04468529: Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 154 | RoW | Recombinant human Neuregulin for injection, Neucardin, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 04/22 | 04/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Guo, YuBiao |
NCT05369312: Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients |
|
|
| Not yet recruiting | 1 | 230 | RoW | BPI-442096 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer | 05/24 | 05/25 | | |
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | APG-2449, APG-2449 Capsule | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma | 01/25 | 02/25 | | |
NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules |
|
|
| Active, not recruiting | N/A | 10560 | RoW | ctDNA methylation analysis by NGS | AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University | Pulmonary Nodules | 09/24 | 06/25 | | |
PRESENTII, NCT06605885: An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients |
|
|
| Recruiting | N/A | 200 | RoW | | AstraZeneca | Asthma | 09/26 | 09/26 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Zeng, Jinsheng |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
HRS-7450-102, NCT06447415: Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial |
|
|
| Recruiting | 1 | 62 | RoW | HRS-7450, 0.9% sodium chloride injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Acute Ischemic Stroke | 12/24 | 03/25 | | |
| Tang, Kejing |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
| Zhong, Bihui |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05193916: A Phase II Clinical Trial of Chiglitazar for NASH |
|
|
| Completed | 2 | 104 | RoW | chiglitazar sodium tablets, Bilessglu®, CS-038, Carfloglitazar, Placebo, simulant of chiglitazar | Chipscreen Biosciences, Ltd. | NASH | 01/24 | 01/24 | | |
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study |
|
|
| Recruiting | N/A | 2500 | RoW | | AstraZeneca | NASH With Fibrosis | 12/26 | 12/26 | | |
| Mao, Ren |
| No trials found |
